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Background: Tumor Treating Fields (TTFields), an anti-mitotic, regional treatment
approved for glioblastoma utilizes low intensity, alternating electric fields delivered
non-invasively to the tumor using a portable medical device. In-vitro, humanmesothe-
lioma cells were highly susceptible to TTFields.
Methods: The trial accrued 80 patients with unresectable, previously untreated meso-
thelioma. Patients were treated with continuous 150 kHz TTFields (>18h/day) in com-
bination with pemetrexed and cisplatin or carboplatin. Inclusion criteria included
ECOG PS of 0-1 and pathologically proven mesothelioma. The primary endpoint was
overall survival (OS). A visual analog scale was used to assess EOCG performance status
and cancer-related pain assessed until disease progression. The sample size provided
80% power with two-sided alpha of 0.05 to detect an increase in median OS of 5.5
months compared to historical controls (Vogelzang, JCO 2003).
Results:All 80 patients had aminimum follow up of 12months. Median age was 67
(range 27-78), 84% were male and 44% (35 patients) had an ECOGPS of 1. 66% (53
patients) had epithelioid histology, similar to the Vogelzang study. Median OS was 18.2
months (95% CI 12.1-25.8) versus 12.1 months in the historical control. Median OS
for epithelioid patients was 21.2 months (95% CI 13.2-25.8). ECOG score was stable
during the first year of follow up. Median time to deterioration in performance status
was 13.1 months. Average score of pain was lower compared to baseline during the first
7 months of the treatment and was higher later on the study, with amedian time to a
clinical significant 33% increase in pain of 8.4 months. No device-related serious
adverse events (AEs) were reported. Expected TTFields-related dermatitis was reported
in 46% (37 patients). Four patients (5%) had grade 3 dermatitis.
Conclusions: The study met primary endpoint of significant extension of overall sur-
vival in previously untreatedmesothelioma patients. TTFields was not associated with
a decrease in performance status or an increase in pain for the duration of TTFields use.
TTFields in combination with chemotherapy is efficacious inmalignant pleural meso-
thelioma compared to historical data.
Clinical trial identification:NCT02397928.
Legal entity responsible for the study:Novocure.
Funding:Novocure.
Disclosure:G.L. Ceresoli, F. Grosso: Travel funds: Novocure. All other authors have
declared no conflicts of interest.
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Background: In patients with malignant pleural mesothelioma (MPM) chemotherapy
is the only treatment modality that has been shown to improve survival. Surgery, by
either pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP) can be
an option of treatment in patients with early stage disease and good functional status,
nevertheless, this modality remains questionable. The aim of this study was to evaluate
the effect of surgical treatment on the survival in patients withMPM.
Methods: Case series of patients with histologically provenMPM between January
2012 and Jun 2015 were reviewed retrospectively. The variables analyzed were: age, sex,
asbestos exposure, smoking history, biomass exposure, performance status with ECOG
scale, staging and type of treatment. Univariate andmultivarite analyses were per-
formed using the Cox regression model. Survival functions were estimated using the
Kaplan-Meier statistics. The decision to perform either P/D or EPP was on the basis
surgeon’s preference.
Results: There were 122 cases of MPM; 71%were males and the media age at diagnosis
was 63 years. Twenty (16.4%) of the cases received surgery, 8 EPP, 8 P/D, and 4 were
unresectable at the moment of the surgery. The 30-day mortality was 5%, one patient
after EPP. The median survival in all cases was 8.6 months, while in the surgical vs no
surgical group was 15.8 vs 7.2 months respectively (p< 0.05). In comparision to no sur-
gery treatment, surgery alone was associated with significant improvement in survival
[adj HR 0.20 (95%CI: 0.07-0.56). At multivariate analysis independent significant
predictors of survival were surgery [adj HR 0.21 (95%CI: 0.06-0.71), beign female
[adj HR 0.49 (95%CI: 1.06-4.48), chemotherapy [adj HR 0.22 (95%CI: 0.07-0.70),
stage early vs advanced [adj HR 0.47 (95%CI: 0.22-1.04) and ECOG< 2 [adj HR 0.21
(95%CI: 0.06-0.76).
Conclusions:Our data suggest relative advantage of surgery on survival. Patients who
received surgery had better survival than patients who were treated with chemotherapy
or palliative care alone.
Legal entity responsible for the study: Instituto Nacional de Enfermedades
Respiratorias.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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Background:Malignant pleural mesothelioma (MPM) is a rare and aggressive thoracic
cancer that has been strongly linked to asbestos exposure. The standard of care treat-
ment for unresectable mesothelioma is cisplatin plus pemetrexed chemotherapy, which
offers modest outcomes. Thus, there is an urgent need to identify more effective treat-
ments for mesothelioma patients. Tumor Treating Fields (TTFields) therapy is an effec-
tive anti-neoplastic treatment modality delivered via noninvasive application of low
intensity, intermediate frequency, alternating electric fields. We explored the potential
use of TTFields alone and in combination with cisplatin or pemetrexed as a treatment
for mesothelioma.
Methods:NCI-H2052 andMSTO-211H cells were treated at various TTFields frequen-
cies for 72 hours using the inovitro system.
Results: The optimal TTFields frequency leading to the highest reduction in cell counts
was 150 kHz for both NCI-H2052 andMSTO-211H cells. TTFields application
(1.1 V/cm, 72 hours) at 150 kHz led to 45%, 51% reduction in cell counts and 64%,
46% reduction in clonogenic potential in NCI-H2052 andMSTO-211H cells, respec-
tively. Efficacy of the combined treatment of TTFields and cisplatin or pemetrexed was
tested by applying TTFields at the optimal frequency together with various drug con-
centrations. The combined treatment of TTFields and cisplatin or pemetrexed led to a
significant reduction in cell count, induction of apoptosis and reduced clonogenic
potential as compared to either modality alone (2-way ANOVA, p< 0.0001(. Safety
studies did not reveal any adverse event associated with 150 kHz TTFields application
to the rat torso.
Conclusions: These results demonstrate that TTFields can be an effective treatment
against mesothelioma cells and that the combination with cisplatin or pemetrexed may
further enhance treatment efficacy. These results are supported by a recent phase 2
study, which reported that MPMpatients treated with the combination of TTFields
with pemetrexed and platinum experienced improved overall survival as compared to
historical control with no increase in systemic toxicity.
Legal entity responsible for the study:Novocure Israel.
Funding:Novocure Israel.
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stock options: Novocure Israel. E. Kirson: Full time employee stock options, stock own-
ership: Novocure Israel; Holds senior leadership position: Novocure Israel.
VC 2019 by the European Lung Cancer Congress organisers, ESMO and IASLC. Published by Oxford University Press.
Annals of Oncology 30 (Supplement 2): ii72–ii73, 2019
doi:10.1093/annonc/mdz069
MESOTHELIOMA
This is an Open Access article under the  CC-BY-NC license.-ND
